Century Therapeutics, Inc. (IPSC) stock intrinsic value fair value estimate & owner earnings analysis

Century Therapeutics is a Philadelphia-based, pre-revenue biotechnology company that engineers induced pluripotent stem cells (iPSCs) into off-the-shelf cell therapies. It has no approved products and no product sales. Its lead program, CNTY-813, is an iPSC-derived insulin-producing islet cell therapy for type 1 diabetes, still in preclinical development with an FDA filing to begin human trials planned for the fourth quarter of 2026 and first clinical data targeted for the second half of 2027. CNTY-308, a CD19-targeted iPSC-derived CAR T cell for B-cell-driven autoimmune diseases, is planned to enter the clinic in 2026, and CNTY-101 continues in an investigator-sponsored autoimmune study. In November 2025 the company narrowed its pipeline to these programs, cut staff and facility costs, and in the second quarter of 2026 gave up part of its facility lease. How the business has performed: every year since inception has consumed cash. On our owner-earnings measure (operating cash flow, with stock-based pay treated as a real cost and all capital spending charged) the business used about $57 million in 2020, $136 million in 2021, $128 million in 2023, $120 million in 2024 and $106 million in 2025. 2022 looked better only because Bristol-Myers Squibb paid a $100 million upfront fee (plus a $50 million share purchase) for a research collaboration; Bristol-Myers Squibb ended that collaboration in March 2025. The $109 million of revenue reported in 2025 is the accounting release of that 2022 payment on termination, not new cash, so we do not count it as 2025 earnings. Excluding those one-offs, the first half of 2026 used about $44 million, an annual pace near $85-90 million, lower than 2025 because of the November 2025 cutbacks. Two consecutive quarters at this lower level are why we use it rather than the older, larger spending levels. What the company owns: $197.2 million of cash and investments at June 30, 2026 (after raising $126.7 million net in a January 2026 private placement at $1.15 per share with half a warrant each), no borrowings, and about 206 million shares including pre-funded warrants. A further 58.7 million warrants are exercisable at $1.75; they would only be exercised above that price and are not counted. The company says its cash lasts into the first quarter of 2029. How we value it: a company with no sales is worth what its evidenced cash flows are worth. Nothing in the filings today, no product revenue, no signed partnership and no royalty, lets us put a dollar figure on the pipeline, so all three cases give it zero value. That is a statement about what can be proven now, not a prediction that the science fails. Every case is therefore the cash on hand minus the present value (at 6%) of the spending needed to run the plan. Base case: spending runs at about $85 million a year, between the first-half 2026 pace and the rate implied by the company's runway guidance, and the full cash balance is spent on the CNTY-813 and CNTY-308 programs by late 2028. The business, before its cash, is worth about minus $185 million (the present value of that spending); it owes no debt and holds $197 million; the difference is about $12 million, or roughly $0.06 per share. At the end of the runway the company has to raise money again, as it did in 2021, 2024 and 2026, and whatever the programs are worth then is not something we can yet evidence. Bear case: moving two programs into human trials pushes spending back to the 2025 level of about $106 million a year, so the cash is gone by around mid-2028. The company has a record of writing off what it acquires: a $16.4 million impairment in 2023, the $4.3 million goodwill from the 2024 Clade acquisition written off the same year, and a further $6.8 million impairment in 2025. At that point roughly $30 million of remaining facility lease payments would still be owed with no cash to meet them, forcing a heavily dilutive raise or a wind-down. The business is worth about minus $213 million against $197 million of cash, so the company would owe roughly $16 million more than it is worth, about minus $0.08 per share. Bull case: the leaner cost base holds at the roughly $75 million a year implied by management's runway guidance, and the first CNTY-813 clinical data arrive on schedule in the second half of 2027. That is the point where the company either has evidence to fund further work or stops. About $85 million of cash would remain, which we value at face and credit nothing more for the programs. Spending to that point is worth about minus $108 million against $197 million of cash, leaving about $89 million, or roughly $0.43 per share. What would make this wrong: a signed partnership with a meaningful non-refundable upfront payment (Century did one with Bristol-Myers Squibb in 2022) or positive human data for CNTY-813 would create value we cannot count today. On the other side, trial costs running above the 2025 level, or another expensive acquisition, would spend the cash faster. Because the plausible outcomes range from slightly below zero to about $0.43, and the median is close to zero after the planned spending, the margin-of-safety price sits far below the cash per share.